Journal
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
Volume 105, Issue 13, Pages 989-992Publisher
OXFORD UNIV PRESS INC
DOI: 10.1093/jnci/djt140
Keywords
-
Categories
Funding
- Public Health Service Grant from the National Cancer Institute, Department of Health and Human Services [U10-CA-37377, U10-CA-69974, U10-CA-12027, U10-CA-69651, U24-CA-114732]
- Genentech Inc
- Sanofi-Synthelabo Inc
- Pennsylvania Department of Health
Ask authors/readers for more resources
National Surgical Adjuvant Breast and Bowel Project protocol C-08 tested the worth of adding 1 year of bevacizumab to oxaliplatin-based standard adjuvant chemotherapy regimen in the treatment of stage II/III colon cancer. Although the overall result was negative, the possibility that a molecularly defined subset could benefit from bevacizumab cannot be ruled out. We performed post hoc Cox regression analyses to test for marker-by-treatment interactions for standard pathological features and survival analyses using the KaplanMeier method. All statistical tests were two-sided and considered statistically significant at the .05 level. Patients diagnosed with mismatch repair defective (dMMR) tumors derived statistically significant survival benefit from the addition of bevacizumab (hazard ratio [HR] 0.52; 95% confidence interval [CI] 0.29 to 0.94; P .02) in contrast with no benefit in patients diagnosed with mismatch repair proficient tumors (HR 1.03; 95% CI 0.84 to 1.27; p .78; P-interaction .04). Although a post hoc finding, this data suggests that a molecularly defined subset of colon cancer patients may derive clinical benefit from antiangiogenesis agents and underscores the need for independent validation in other clinical trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available